Arcturus Therapeutics Holdings Inc
ARCT.O- Latest Trade
- trading lower20USD
- -0.02
- 0.10%
- As of Jan 26 2023. Values delayed up to 15 minutes
- Day Range
- 19.50 - 20.48
- 52-Week Range
- 11.70 - 31.41
- Previous Close
- 20.02
- Open
- 20.38
- Volume
- 186,307.00
- 3 Month Average Trading Volume
- 11.81
- Shares Out (Mil)
- 26.49
- Market Cap
- 530.39
- Forward P/E
- -6.27
- Dividend Yield
- 0.00
Key Statistics
2.63636364 mean rating - 11 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 10.30
- Price To Book (Quarterly)
- 3.64
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 41.01
- Long Term Debt/Equity (Quarterly)
- 21.99
- Return On Investment (TTM)
- -54.92
- Return On Equity (TTM)
- -40.28
2021 (millions USD)
About Arcturus Therapeutics Holdings Inc (ARCT.O)
Company Information
Arcturus Therapeutics Holdings Inc. is a late-stage global clinical messenger ribonucleic acid (mRNA) medicines company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The Company's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
Address
10628 Science Center Dr Ste 250SAN DIEGO, CA
92121-1132
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Peter C. Farrell
- Independent Chairman of the Board
- Joseph E. Payne
- President, Chief Executive Officer, Director
- Andrew H. Sassine
- Chief Financial Officer, Director
- Padmanabh Chivukula
- Chief Operating Officer, Chief Scientific Officer
- Lance Kurata
- Chief Legal Officer
- Kelly Lindert
- Chief Development Officer - Vaccines
- John H. Markels
- Director
- James F. Barlow
- Independent Director
- Edward W. Holmes
- Independent Director
- Jing L. Marantz
- Independent Director
- Magda Marquet
- Independent Director
Latest News
- BusinessAustralia's CSL in mRNA vaccine licensing deal with U.S.-based Arcturus
Australia's CSL Ltd said on Wednesday it had struck a licensing deal with Arcturus Therapeutics Holdings Inc that would help it gain access to the U.S. drug developer's messenger RNA (mRNA) vaccine technology.
- BusinessArcturus to start clinical trial of COVID-19 vaccine in Vietnam
Arcturus Therapeutics Holdings Inc (ARCT.O) said on Monday its Vietnamese partner received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in the Southeast Asian country.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,929.10 | -- |
| Copper | 792.80 | -- |
| Brent Crude Oil | 87.66 | 0.22% |
| CBOT Soybeans | 1,522.50 | 0.07% |
Stocks
| Index | Last | % Change |
|---|---|---|
| -- | -- | -- |
| -- | -- | -- |
| -- | -- | -- |
| -- | -- | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes